BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...PDUFA date of June 25. Elizabeth S. Eaton Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Ocaliva, obeticholic acid (DSP-1747...
BioCentury | Jun 29, 2020
Regulation

Intercept: Surrogate endpoint not enough for FDA to approve NASH therapy

...each fell 5%. Targets FXR (NR1H4) - Farnesoid X receptor Paul Bonanos, Associate Editor Ocaliva, obeticholic acid (DSP-1747...
BioCentury | Jun 17, 2020
Product Development

Daily Chart: Inventiva vs. Intercept in NASH

...for Lanifibranor and an 18-month readout for obeticholic acid. Stephen Hansen, Associate Editor lanifibranor (iva337) Ocaliva, obeticholic acid (DSP-1747...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

...Auroro, Colo. email: nathan.dahl@childrenscolorado.org CONTACT: Rajeev Vibhakar, same affiliation as above email: rajeev.vibhakar@ucdenver.edu Claire Quang alvocidib, flavopiridol (DSP-2033...
BioCentury | May 23, 2020
Product Development

Further delays at FDA for Intercept’s NASH therapy

...Intercept markets obeticholic acid as Ocaliva for primary biliary cholangitis. Sandi Wong, Assistant Editor Ocaliva, obeticholic acid (DSP-1747...
BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

Pivotal bioVentures, crossovers back Akouos in $105M series B Akouos Inc., a gene therapy company developing treatments for hearing loss, raised $105 million in a series B round led by Pivotal bioVentures. New investors included...
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

...develop compounds for psychiatric disorders, announced Thursday they had initiated a Phase I study of DSP-1181...
...agonist. The receptor is the target of multiple commercial- and clinical-stage compounds for neuropsychiatric diseases. DSP-1181...
...Discoidin domain receptor tyrosine kinase 1 Karen Tkach Tuzman, Associate Editor Exscientia Ltd. Dainippon Sumitomo Pharma Co. Ltd. AI DSP-1181 University...
BioCentury | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

...Editor and Paul Bonanos, Associate Editor Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) Ocaliva, obeticholic acid (DSP-1747...
BioCentury | Dec 14, 2019
Company News

Dec. 13 Company Quick Takes: Horizon, Intercept, Imfinzi, Evenity and Numab-3SBio

...Writers Imfinzi, durvalumab (MEDI4736) Evenity, romosozumab (AMG 785, CDP7851, anti-sclerostin antibody) teprotumumab (HZN-001, RV001, r1507, rg1507) Ocaliva, obeticholic acid (DSP-1747...
BioCentury | Nov 26, 2019
Company News

Priority Review roundup: Roche-PTC, Intercept, Zogenix

...Survival of motor neuron 2 centromeric Hongjiang Li, Staff Writer risdiplam (RG7916, RO7034067) Fintepla (ZX008, brabafen) Ocaliva, obeticholic acid (DSP-1747...
Items per page:
1 - 10 of 113